US 12,325,745 B2
Anti-DLL3 antibodies and uses thereof
Minghan Wang, San Diego, CA (US); Hui Zou, San Diego, CA (US); and Haiqun Jia, San Diego, CA (US)
Assigned to Phanes Therapeutics, Inc., San Diego, CA (US)
Filed by Phanes Therapeutics, Inc., San Diego, CA (US)
Filed on Jun. 4, 2024, as Appl. No. 18/733,287.
Application 18/733,287 is a division of application No. 15/733,747, granted, now 12,037,391, previously published as PCT/US2019/029888, filed on Apr. 30, 2019.
Claims priority of provisional application 62/668,427, filed on May 8, 2018.
Claims priority of provisional application 62/754,207, filed on Nov. 1, 2018.
Claims priority of provisional application 62/787,815, filed on Jan. 3, 2019.
Prior Publication US 2024/0383979 A1, Nov. 21, 2024
Int. Cl. A61K 39/395 (2006.01); A61K 39/00 (2006.01); C07K 16/00 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C07K 16/46 (2006.01); G01N 33/574 (2006.01)
CPC C07K 16/28 (2013.01) [C07K 16/2803 (2013.01); C07K 16/30 (2013.01); G01N 33/57492 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/92 (2013.01)] 8 Claims
 
1. An isolated humanized anti-CD47/DLL3 bispecific antibody or antigen-binding fragment thereof comprising a first antigen-binding domain that specifically binds CD47, and a second antigen-binding domain that specifically binds DLL3, wherein the first antigen-binding domain comprises a heavy chain complementarity determining region 1 (HCDR1), HCDR2, HCDR3, having the polypeptide sequences of SEQ ID NOs: 178, 179 and 180 or SEQ ID NOs: 187, 188, and 189; the second antigen-binding domain comprises a heavy chain complementarity determining region 1 (HCDR1), HCDR2, HCDR3, having the polypeptide sequences of SEQ ID NOs: 181, 182 and 183 or SEQ ID NOs: 190, 191, and 192; and the first antigen-binding domain and the second antigen-binding domain each comprises a light chain complementarity determining region 1 (LCDR1), LCDR2, and LCDR3, having the polypeptide sequences of SEQ ID NOs: 184, KAS and 186 or SEQ ID NOs: 193, 194, and 195.